Celgene To Appeal Against Negative NICE Recommendation On Vidaza
The appeal Celgene expects to file will detail that Vidaza as a treatment for MDS meets not only the end of life criteria (as set out by the
The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has recommended a routine programme with the 4CMenB vaccine for adolescents.